COHBAR
CohBar is a clinical-stage biotechnology company that focuses on the research and development of mitochondria based therapeutics. It has developed proprietary mitochondria based therapeutic (MBT) platform technology, using cell-based assays and animal models of disease, to rapidly identify naturally occurring MDPs with promising biological activity. The company was founded in 2007 and is headquartered in Menlo Park, California.
COHBAR
Social Links:
Industry:
Biotechnology Developer Platform Therapeutics
Founded:
2007-01-01
Address:
Menlo Park, California, United States
Country:
United States
Website Url:
http://www.cohbar.com
Total Employee:
1+
Status:
Active
Contact:
4153818980
Email Addresses:
[email protected]
Total Funding:
24.55 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Apache Microsoft Exchange Online Amazon Office 365 Mail
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
InQ Biosciences
InQ Biosciences provides integrated cell growth and cell analysis systems for research and development in the cell and tissue growth sector.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.cohbar.com Semrush global rank: 3.63 M Semrush visits lastest month: 3.92 K
Unable to get host informations!!!
More informations about "CohBar"
CohBar - Crunchbase Company Profile & Funding
CohBar is a clinical-stage biotechnology company that focuses on the research and development of mitochondria based therapeutics. It has developed …See details»
CohBar, Inc.
The Company is no longer operating. Any questions may be submitted by email to: [email protected]. Previous SEC filings for the Company can be found at: …See details»
CohBar - MitoWorld
CohBar is a clinical-stage biotechnology company exploiting the power of the mitochondria and its encoded peptides to develop potential breakthrough therapeutics targeting chronic and age-related diseases. While extensive work …See details»
CohBar - Overview, News & Similar companies | ZoomInfo.com
Jun 5, 2023 Who is CohBar. CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an …See details»
SEC.gov
Note 1 - Business Organization and Nature of Operations CohBar, Inc. (“CohBar,” “its” or the “Company”) is a clinical stage biotechnology company leveraging the power of the …See details»
CohBar Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 CohBar is a clinical-stage biotechnology company focused on the research and development of mitochondria based therapeutics. It aims to treat a range of diseases …See details»
CohBar, Inc. (CWBR) Company Profile & Overview - Stock Analysis
Jan 23, 2025 CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops …See details»
CohBar - Funding, Financials, Valuation & Investors - Crunchbase
CohBar is a clinical-stage biotechnology company that focuses on the research and development of mitochondria based therapeutics. ... Log In. Log In. Experience the new Crunchbase, …See details»
CohBar - VentureRadar
" CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and …See details»
CohBar, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore CohBar, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 31 news, and 2 literature, Disease Domain:Endocrinology and Metabolic Disease, Technology …See details»
CohBar, Inc. (CWBR): history, ownership, mission, how it works
[relinking] Home History Owners Mission How It Works How It Makes Money CohBar, Inc. (CWBR) InformationA Brief History of CohBar, Inc. (CWBR) CohBar, Inc. is a clinical stage …See details»
CohBar, Inc. | LinkedIn
CohBar, Inc. | ١٬٥٤٨ من المتابعين على LinkedIn. CohBar is a clinical-stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop …See details»
CohBar Provides Update on the Phase 1a/1b Clinical Trial for …
Jul 14, 2021 The process of data entry and final validation by the company’s clinical research organization. MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. …See details»
CohBar Inc. Company Profile 2025: A Comprehensive SWOT, …
CohBar Inc. Company Profile is a detailed strategic and analytical report on CohBar Inc.. The 2025 version of the report offers detailed insights into the company’s ... employee count, …See details»
CohBar Founder Dr. Nir Barzilai Awarded the 2018 Fondation
Nov 26, 2018 Honored for his groundbreaking research on the determinants of longevity in human centenarians and associated models. November 26, 2018 09:00 ET | Source: CohBar, …See details»
CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors
MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria …See details»
CohBar to Present at the H.C. Wainwright Global Life
Feb 25, 2021 CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of …See details»
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive ... - ADVFN
Feb 27, 2025 CohBar, Inc. (NASDAQ: CWBR) (“CohBar” or the “company”) and Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotechnology company …See details»
CohBar Reports Fourth Quarter and Full-Year 2021 Financial
Mar 29, 2022 CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update Conference call and webcast at 5:00 p.m. ET today, March 29, …See details»
THERAPEUTIC MITOCHONDRIAL PEPTIDES, 62/885,394 (U.S. Pat.
Case docket: THERAPEUTIC MITOCHONDRIAL PEPTIDES, 62/885,394 in U.S. Patent Application, last filing 08/16/2020, filed 08/12/2019.See details»